Xiao Rong, Jin Hao, Huang Fang, Huang Biao, Wang Hui, Wang Yi-Gang
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China.
Department of Pathology, Laboratory Medicine Center, Zhejiang Provincial Peoples' Hospital, Peoples' Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China.
World J Gastrointest Oncol. 2024 Jul 15;16(7):2867-2876. doi: 10.4251/wjgo.v16.i7.2867.
Hepatocellular carcinoma (HCC) is a systemic disease with augmented malignant degree, high mortality and poor prognosis. Since the establishment of the immune mechanism of tumor therapy, people have realized that immunotherapy is an effective means for improvement of HCC patient prognosis. Oncolytic virus is a novel immunotherapy drug, which kills tumor cells and exempts normal cells by directly lysing tumor and inducing anti-tumor immune response, and it has been extensively examined as an HCC therapy. This editorial discusses oncolytic viruses for the treatment of HCC, emphasizing viral immunotherapy strategies and clinical applications related to HCC.
肝细胞癌（HCC）是一种恶性程度高、死亡率高且预后差的全身性疾病。自肿瘤治疗免疫机制确立以来，人们认识到免疫治疗是改善HCC患者预后的有效手段。溶瘤病毒是一种新型免疫治疗药物，它通过直接裂解肿瘤和诱导抗肿瘤免疫反应来杀死肿瘤细胞并使正常细胞免受影响，并且作为一种HCC治疗方法已得到广泛研究。这篇社论讨论了用于治疗HCC的溶瘤病毒，重点强调了与HCC相关的病毒免疫治疗策略和临床应用。
